Cancer name Multiple Myeloma
Cancer Type MM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment MiR-29b
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature CD86+ DCs
Official Symbol Dendritic cell
Mode of action CE_D_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental cell lines
Description Enforced expression of miR-29b mimics in DCs co-cultured with MM cells or LPS significantly reduced double positive CD83/CD86 mature DCs at 48h and according to MAP prediction, a significant downregulation of the surface expression of the costimulatory molecule CD86 and of the immune regulatory antigen B7H3, which is a validated miR-29 target 38, was found.
PMID 29158557
Title MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells